Steven Katz, MD
Psychiatry · Hartford, CTNPI 1679502140
Payments from drug & device makers
Across 1,189 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Lundbeck LLC$1K
- Corium, LLC$1K
- Bausch Health US, LLC$1K
- Sunovion Pharmaceuticals Inc.$1K
- plus $10K from 25 others
What the payments were for
- Food & beverage$18,25299%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 198 | $2,450 |
| Teva Pharmaceuticals USA, Inc. | 80 | $1,553 |
| Lundbeck LLC | 80 | $1,401 |
| Corium, LLC | 94 | $1,240 |
| Bausch Health US, LLC | 69 | $1,149 |
| Sunovion Pharmaceuticals Inc. | 109 | $1,077 |
| Neurocrine Biosciences, Inc. | 64 | $1,076 |
| Johnson & Johnson | 67 | $1,063 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,036 |
| Vanda Pharmaceuticals Inc. | 58 | $919 |
| Alkermes, Inc. | 39 | $807 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $776 |
| Axsome Therapeutics, Inc. | 31 | $700 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $643 |
| Eisai Inc. | 25 | $389 |
| E.r. Squibb & Sons, L.L.C. | 20 | $368 |
| Almatica Pharma LLC | 16 | $265 |
| Ironshore Pharmaceuticals Inc. | 11 | $223 |
| Idorsia Pharmaceuticals US Inc | 16 | $208 |
| Vertical Pharmaceuticals, LLC | 11 | $195 |
| Merck | 10 | $152 |
| Orexo US, Inc. | 8 | $132 |
| Adlon Therapeutics L.p. | 7 | $129 |
| Neos Therapeutics, LP | 6 | $112 |
| Collegium Pharmaceutical, Inc. | 5 | $97 |
| Jazz Pharmaceuticals Inc. | 4 | $75 |
| Tris Pharma Inc | 4 | $66 |
| Indivior Inc. | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| TMS Neurohealth Centers Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
How this compares
$18,383 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 123 | $194,743 |
| IngrezzaValbenazine Tosylate | 22 | $178,653 |
| AustedoDeutetrabenazine | 11 | $166,249 |
| Austedo XrDeutetrabenazine | 18 | $118,643 |
| RexultiBrexpiprazole | 47 | $67,507 |
| CaplytaLumateperone Tosylate | 34 | $53,103 |
| Invega SustennaPaliperidone Palmitate | 13 | $28,573 |
| AdderallDextroamphetamine/Amphetamine | 28 | $22,985 |
| BelsomraSuvorexant | 48 | $21,368 |
| VyvanseLisdexamfetamine Dimesylate | 42 | $20,262 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 136 | $19,527 |
| PristiqDesvenlafaxine Succinate | 15 | $17,850 |
| TrintellixVortioxetine Hydrobromide | 18 | $14,166 |
| Adderall XrDextroamphetamine/Amphetamine | 22 | $11,453 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 11 | $9,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,553 | $284,89229 claims |
| AbbVieVraylar | $2,450 | $194,743123 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,076 | $178,65322 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,036 | $67,50747 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall, Vyvanse, Trintellix | $643 | $57,41388 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $776 | $53,10334 claims |
| Johnson & JohnsonInvega Sustenna, Concerta | $1,063 | $38,38826 claims |
| MerckBelsomra | $152 | $21,36848 claims |
| Orexo US, Inc.Zubsolv | $132 | $9,94411 claims |
| Eisai Inc.Dayvigo | $389 | $7,16518 claims |
| Almatica Pharma LLCLoreev Xr | $265 | $5,27012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Hartford
- Sara NiegoHartford$25K
- Mirela LoftusHartford$24K
- Vladimir CoricNew Haven$133.7M
- Christopher VandyckNew Haven$20.8M
- Bart SloanNorwalk$6.8M
- Adam MeccaNew Haven$5.1M
- David MatuskeyFarmington$3M
- Donald AmmermanDanbury$1.5M
- Mahmoud OkashaNorwich$1.4M
- Gerard SanacoraNew Haven$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.